How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Burns Drug Market
- By Drug Type: Topical Antimicrobials, Analgesics, Anti-inflammatory Agents, Growth Factors, Enzymatic Debriding Agents
- By Burn Severity: First-degree Burns, Second-degree Burns, Third-degree Burns, Fourth-degree Burns
- By Formulation: Creams, Ointments, Sprays, Gels, Hydrogel Dressings
- By Application Method: Topical Application, Intravenous Administration, Oral Administration
- By End User: Hospitals, Burn Centers, Clinics, Home Care Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Topical Antimicrobials leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Burns Drug Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Burn Severity 4
Formulation 5
Application Method 3
End User 4
Companies profiled
Smith & Nephew
3M
Mölnlycke Health Care
ConvaTec
Medline Industries
Coloplast
Derma Sciences (Integra LifeSciences)
Systagenix (Acelity)
Hollister Incorporated
Beiersdorf AG
Urgo Medical
KCI Medical (Acelity)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Smith & Nephew
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →3M
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mölnlycke Health Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ConvaTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Medline Industries
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Coloplast
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Derma Sciences (Integra LifeSciences)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Systagenix (Acelity)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hollister Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Beiersdorf AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Urgo Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →KCI Medical (Acelity)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Baxter International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Molnlycke Health Care
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Essity
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,858M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Topical Antimicrobials56.2
- Analgesics14.0
- Anti-inflammatory Agents13.8
- Growth Factors8.1
- Enzymatic Debriding Agents7.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,803M → $4,416M · 11.8%
Europe$1,257M → $2,725M · 10.2%
Asia Pacific$1,147M → $2,795M · 11.8%
Latin America$710.3M → $1,842M · 12.6%
Middle East and Africa$546.4M → $1,325M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.252026
11.262027
11.272028
11.272029
11.302030
11.302031
11.312032
11.332033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Smith & Nephew14.4
- 3M14.0
- Mölnlycke Health Care11.4
- ConvaTec10.0
- Medline Industries11.3
- Coloplast11.1
- Others27.8
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type15.2%
Burn Severity24.8%
Formulation25.1%
Application Method16.6%
End User18.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.7
- Europe20.8
- Asia Pacific21.3
- Latin America14.1
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Smith & Nephew | 96 | 99 | 85 | 87 | 94 | 98 | 93 |
| 3M | 90 | 81 | 92 | 80 | 68 | 81 | 82 |
| Mölnlycke Health Care | 63 | 73 | 77 | 65 | 68 | 74 | 70 |
| ConvaTec | 63 | 72 | 68 | 64 | 62 | 62 | 65 |
| Medline Industries | 64 | 65 | 60 | 56 | 51 | 70 | 61 |
| Coloplast | 56 | 54 | 65 | 63 | 47 | 50 | 56 |
| Derma Sciences (Integra LifeSciences) | 57 | 51 | 58 | 54 | 44 | 60 | 54 |
| Systagenix (Acelity) | 48 | 60 | 39 | 45 | 43 | 60 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Smith & Nephew
- 3M
- Mölnlycke Health Care
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Smith & Nephew | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 3M | ✓ | ◐ | ✓ | ◐ | − | ✓ |
| Mölnlycke Health Care | − | ◐ | ◐ | ✓ | ◐ | ✓ |
| ConvaTec | ◐ | ✓ | ◐ | ◐ | − | − |
| Medline Industries | ◐ | ◐ | − | − | ◐ | ✓ |
| Coloplast | ◐ | − | ◐ | ◐ | − | ◐ |
| Derma Sciences (Integra LifeSciences) | − | − | − | − | − | ◐ |
| Systagenix (Acelity) | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Smith & Nephew93
23M82
3Mölnlycke Health Care70
4ConvaTec65
5Medline Industries61
6Coloplast56
7Derma Sciences (Integra LifeSciences)54
8Systagenix (Acelity)49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Smith & Nephew3M
Challenger1
Strong scale, closing on the leaders.
Mölnlycke Health Care
Contender2
Focused players with pockets of strength.
ConvaTecMedline Industries
Niche3
Specialists in a single segment or region.
ColoplastDerma Sciences (Integra LifeSciences)Systagenix (Acelity)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Burns Drug Market — a $434M beachhead inside a $7.33B market.
Beachhead (SOM)$434Mobtainable near-term
Serviceable (SAM)$2.69Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Topical Antimicrobials
Best fit — highest urgency & budget in Drug Type.
Economic buyer75 fit
Analgesics
Strong fit — clear ROI and a fast path to value.
End user70 fit
Anti-inflammatory Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Burn Severity & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Formulation
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Burns Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation14%
Closed-won5%
$13.5KCAC
$73KLTV
5.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Burns Drug Market is a resilient opportunity — $6.49B by 2033, compounding at 5.2%.
TAM · 2025$4.34Btoday
TAM · 2033$6.49Bforecast
CAGR5.2%2027–2033
Cumulative$48.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.49BTotal addressable market
SAM$2.30BServiceable available market
SOM$466MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.2% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.49BLarge & growingTAM by 2033 at 5.2% CAGR
$2.30BServiceable nowreachable with today’s model
$466MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.07BBear3.4% CAGR
$6.49BBase5.2% CAGR
$8.31BBull6.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Burn Severity optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Burns Drug Market — a $4.00B market by 2033. Plan: grow share from 6.7% to 13.8%.
Market size · 2033$4.00Btotal addressable
Market CAGR4.8%2027–2033
Target share13.8%from 6.7% today
Revenue ambition$552Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 13.8% | At risk |
| Revenue | $288M | $552M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 28.1% | 40.0% | Ahead |
| Customer retention | 88.2% | 96.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Burn Severity capability
A defensible second engine — invest in Burn Severity to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Burn Severity
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $63M capacity & capability investment
- Greenlight bolt-on M&A in Burn Severity
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Burns Drug Market conversation — a $8.51B market you can size, segment and defend in minutes.
Market size · 2033$8.51Btotal opportunity
Growth11.5%CAGR to 2033
Addressable buyers1,522+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 2 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Smith & Nephew3MMölnlycke Health CareConvaTecMedline IndustriesColoplastDerma Sciences (Integra LifeSciences)Systagenix (Acelity)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Burns Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Burns Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Burr Pump Market
Market size, share, segmentation and regional forecast.
$834M market · 2025 base year
View reportBurr Set Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBurrs Market
Market size, share, segmentation and regional forecast.
$553M market · 2025 base year
View reportBursting Disc Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportBursting Strength Testing Machines Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBus and Coach Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportBus Bar Terminal Market
Market size, share, segmentation and regional forecast.
$478M market · 2025 base year
View reportBus CNG Systems Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportBus Duct Service Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportBus Gearbox Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBus HVAC System Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportBus Line Machine Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.